HSA — authorised 12 December 2019
- Marketing authorisation holder: SAREPTA THERAPS INC
- Status: likely_approved
HSA authorised Vyondys 53 on 12 December 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. HSA authorised it on 12 December 2019.
SAREPTA THERAPS INC holds the Singaporean marketing authorisation.